MST1 and CPNE1 Emerge as Candidate Targets in Breast Cancer: Integration of Mendelian Randomization, Multi-omics Validation, and Functional Interrogation
Aug 2026· Breast Cancer· Vol 18, pp. 1-18· 0 citations· 42 references
Medicine
TL;DR
The findings support context-dependent candidate roles and justify mechanistic, in vivo, and formal interaction studies, but do not yet establish therapeutic efficacy or synergy.
Abstract
Background Breast cancer remains a leading cause of female mortality worldwide, with therapeutic benefit limited by tumor heterogeneity and drug resistance. Identification of novel therapeutic targets through integration of genetic causality inference and functional validation is urgently needed. Methods Plasma protein quantitative trait loci (pQTL) from the Fenland cohort (~10,700 individuals) and the FinnGen R10 SomaScan subset (n = 828) were integrated with breast cancer genome-wide association study data from the Breast Cancer Association Consortium (122,977 cases and 105,974 controls). Causal protein-disease relationships were inferred using summary-data-based Mendelian randomization (SMR), with colocalization and HEIDI tests. Multi-level validation was performed using TCGA-BRCA transcriptomic data. Functional validation included CCK-8, EdU, wound healing, Transwell invasion, and flow cytometry apoptosis analysis evaluated CPNE1 knocdown and/or overexpression of the MST1 gene which encodes macrophage-simulating protein (MSP). Results SMR identified 23 proteins in Fenland and 10 in FinnGen at FDR < 0.05. MST1/MSP and CPNE1 were supported in both datasets with PP.H4 ≥ 0.80 and non-significant HEIDI tests. Genetically predicted circulating MSP was positively associated with breast cancer risk, whereas circulating CPNE1 showed an inverse association. TCGA-BRCA showed higher CPNE1 mRNA in tumors (P = 2.57×10⁻25) and lower MST1 mRNA (P = 3.04×10⁻23). CPNE1 expression was highest in triple-negative breast cancer and correlated positively with clinical stage (ρ = 0.211), whereas MST1 expression was lowest in triple-negative breast cancer and correlated inversely with stage (ρ = −0.164). In T47D and MDA-MB-231 cells, CPNE1 knockdown and MST1 overexpression each reduced proliferation, migration, and invasion and increased apoptosis; the combined group showed greater changes than either single intervention. Conclusion This study prioritizes the MST1 gene, which encodes MSP, and CPNE1 as candidate proteins for further investigation in breast cancer. However, the circulating-protein associations, tumor-mRNA patterns, and cell-autonomous perturbations represent distinct and directionally discordant biological contexts. The findings therefore support context-dependent candidate roles and justify mechanistic, in vivo, and formal interaction studies, but do not yet establish therapeutic efficacy or synergy.
Convergent genetic, transcriptomic, and protein-level evidence prioritizes CDC16 as a GC-associated candidate tissue marker whose expression is closely linked to proliferative activity.
Fan Xue, Dao-Cheng Wu, Xu Zhang· International Journal of Bio...· 0 citations
Immune checkpoint inhibitors are used to treat head and neck cancer (HNC), but clinical responses vary, and systematic genetic evaluation is needed to prioritize candidate susceptibility genes. We applied summary-data-based Mendelian randomization (SMR) and HEIDI testing to screen 624 immune checkpoint–related genes, i...
Meng-Jie Zheng, Hao Zhu, Jun Kong et al.· Functional & Integrative Gen...· 0 citations
SIRPG is identified as an immune-related prognostic hub and context-dependent tumor-cell regulator associated with apoptosis, immune communication and spatial microenvironmental organization in HNSCC.
Jiaqi Tang, Yu-Lun He, Yu-Qi Wang et al.· Frontiers in Immunology· 0 citations
PPAP2C exhibits the most significant overexpression pattern across 33 cancer types and was significantly associated with advanced clinical stages and aggressive subtypes (HER2+ and TNBC).
Xiao-Xi Lin, Li-Hang Cen, Si-Hui Yue et al.· Frontiers in Pharmacology· 0 citations
An integrative single-cell eQTL-driven multi-omics framework to identify immune cell-specific causal genes and prioritize drug-repurposing candidates for HNC supports AIM1 and ANXA1 as promising biomarkers and therapeutic entry points for precision drug development.
Zhangwei Xue, Guo-Hang Shen, Gongbiao Lin et al.· Frontiers in Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.